1. Home
  2. INBS vs BGLC Comparison

INBS vs BGLC Comparison

Compare INBS & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INBS
  • BGLC
  • Stock Information
  • Founded
  • INBS 2016
  • BGLC 2017
  • Country
  • INBS United States
  • BGLC Malaysia
  • Employees
  • INBS N/A
  • BGLC N/A
  • Industry
  • INBS Medical Specialities
  • BGLC Medical Specialities
  • Sector
  • INBS Health Care
  • BGLC Health Care
  • Exchange
  • INBS Nasdaq
  • BGLC Nasdaq
  • Market Cap
  • INBS 6.4M
  • BGLC 5.8M
  • IPO Year
  • INBS N/A
  • BGLC N/A
  • Fundamental
  • Price
  • INBS $1.42
  • BGLC $0.34
  • Analyst Decision
  • INBS
  • BGLC
  • Analyst Count
  • INBS 0
  • BGLC 0
  • Target Price
  • INBS N/A
  • BGLC N/A
  • AVG Volume (30 Days)
  • INBS 65.8K
  • BGLC 10.9M
  • Earning Date
  • INBS 02-07-2025
  • BGLC 02-20-2025
  • Dividend Yield
  • INBS N/A
  • BGLC N/A
  • EPS Growth
  • INBS N/A
  • BGLC N/A
  • EPS
  • INBS N/A
  • BGLC N/A
  • Revenue
  • INBS $3,187,974.00
  • BGLC $9,259,858.00
  • Revenue This Year
  • INBS $280.88
  • BGLC N/A
  • Revenue Next Year
  • INBS $126.26
  • BGLC N/A
  • P/E Ratio
  • INBS N/A
  • BGLC N/A
  • Revenue Growth
  • INBS 55.29
  • BGLC N/A
  • 52 Week Low
  • INBS $1.00
  • BGLC $0.21
  • 52 Week High
  • INBS $11.70
  • BGLC $3.39
  • Technical
  • Relative Strength Index (RSI)
  • INBS 48.80
  • BGLC 54.32
  • Support Level
  • INBS $1.36
  • BGLC $0.33
  • Resistance Level
  • INBS $1.47
  • BGLC $0.41
  • Average True Range (ATR)
  • INBS 0.08
  • BGLC 0.11
  • MACD
  • INBS 0.01
  • BGLC 0.00
  • Stochastic Oscillator
  • INBS 48.15
  • BGLC 13.21

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Share on Social Networks: